Health Catalyst, Inc. (NASDAQ:HCAT) Stock Holdings Boosted by Primecap Management Co. CA

Primecap Management Co. CA lifted its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 1.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,404,462 shares of the company’s stock after buying an additional 25,000 shares during the period. Primecap Management Co. CA’s holdings in Health Catalyst were worth $19,572,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Kennedy Capital Management LLC bought a new stake in Health Catalyst during the first quarter worth approximately $8,780,000. Janney Montgomery Scott LLC bought a new stake in shares of Health Catalyst during the 3rd quarter worth $897,000. Essex Investment Management Co. LLC acquired a new position in shares of Health Catalyst in the 3rd quarter worth $2,012,000. AQR Capital Management LLC acquired a new stake in shares of Health Catalyst during the second quarter worth $564,000. Finally, Impax Asset Management Group plc lifted its holdings in shares of Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after purchasing an additional 360,201 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Insider Activity at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This represents a 5.49 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Price Performance

HCAT opened at $8.13 on Friday. The stock has a fifty day moving average price of $8.13 and a 200 day moving average price of $7.26. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The stock has a market cap of $494.69 million, a price-to-earnings ratio of -6.02 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period last year, the business earned ($0.22) earnings per share. Analysts forecast that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HCAT. Evercore ISI boosted their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. JPMorgan Chase & Co. upped their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Finally, Piper Sandler lowered their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.71.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.